AGC
LXRX icon

Alden Global Capital’s Lexicon Pharmaceuticals LXRX Stock Holding History

Alden Global Capital’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-128,700
Closed -$851K – 21
2015
Q1 		$851K Buy
+128,700
New +$879K 0.61% 19

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return

Alden Global Capital's LXRX Position: Q2 2015 in Review

Alden Global Capital sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2015, closing a stake of 128,700 shares — an estimated $851K sold.

Alden Global Capital first reported a position in LXRX in Q1 2015 and held it in 1 quarter. The position peaked at $851K in Q1 2015. 94 funds tracked by Wall St. Rank hold LXRX as of Q2 2015.

  • Alden Global Capital reported no remaining Lexicon Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Alden Global Capital sold 128,700 Lexicon Pharmaceuticals shares in Q2 2015, an estimated $851K.
  • Alden Global Capital first reported a position in Lexicon Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Alden Global Capital's Lexicon Pharmaceuticals position peaked at $851K in Q1 2015.
  • 94 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2015.

Based on Alden Global Capital's 13F filing for Q2 2015, filed 14 Aug 2015.